Why Grail Stock Skyrocketed Nearly 70% In A Week. And What To Watch Next.
Grail stock has surged following an FDA advisory committee's positive recommendation for its cancer-detecting blood test, Galleri. The company is now awaiting final regulatory approval to enter the broader cancer screening market.
Why it matters
FDA approval of a multi-cancer early detection test could significantly disrupt the oncology diagnostics market and improve patient outcomes.
Grail (GRAL) stock has catapulted in September, reaching a record high, as the Food and Drug Administration mulls its Galleri blood test, a contender in the multibillion-dollar cancer detection market. Earlier in the month, an FDA advisory committee backed Galleri's safety and effectiveness, saying the benefits outweigh the risks. Now, Galleri is on the cusp of a full approval. Though...
9/24/2026 Grail stock surged Thursday after a panel of advisors to the FDA backed the company's cancer-detecting blood test.
9/24/2026 Grail stock surged Thursday after a panel of advisors to...
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in